E1R (10?μM) does not displace the radioligand. However, in Jurkat cells, it instead increases the specific binding of a non-selective radioligand ([3H]1,3-di(2-tolyl)guanidine) for the sigma receptor by 38%. The only target for E1R (inhibition or enhancement of radioligand binding exceeding 20%) is the sigma receptor.

E1R (0.1-10?mg/kg; i.p. 60?min before the training session) treatment obviously improves cognitive function in a dose-related manner in mice. E1R demonstrates efficacy against scopolamine-induced cholinergic dysfunction in mice.